PriyankaPulla

@PriyankaPulla

Journalist, freelance. Cover science policy, medicine. If you use a mask, use it like this:

Bangalore
Joined November 2008
170 Photos and videos Photos and videos

Tweets

You blocked @PriyankaPulla

Are you sure you want to view these Tweets? Viewing Tweets won't unblock @PriyankaPulla

  1. Pinned Tweet
    11 Aug 2017

    Here's a disease you don't want to get, even if it is easy to treat. It's coz your doc will probably misdiagnose you

    8 replies 27 retweets 82 likes
    Undo
  2. Retweeted
    6 hours ago
    Replying to and

    I think we're both arguing for the same side if you consider this a debate. It is very easy to chose thresholds that demonstrate a particular result so best to publish some form of sensitivity analysis alongside to show how a different threshold would perform.

    1 reply 1 retweet
    Undo
  3. Retweeted
    8 hours ago

    Layer 2 is related to but distinct from layer 1. Try your best to be the one who finds the limitations or flaws in your findings and esp interpretations, before anyone else does. Fix flaws / limitations if you can; highlight them in Discussion if you can't

    4 replies 33 retweets 231 likes
    Show this thread
    Show this thread
    Undo
  4. 7 hours ago

    very good!

    Good thread on science & publishing
    1 reply 2 likes
    Undo
  5. Retweeted
    8 hours ago
    Replying to

    How many examples don’t we have of drugs we knew was safe in one situation, turning out to be harmful in another? Thalidomide in pregnancy, sodium channel blockers in myocardial infarction, and certainly aspirin in kids with viral infections.

    1 reply 4 retweets 4 likes
    Undo
  6. Retweeted
    9 hours ago
    Replying to

    There is never 'not a time' for RCTs, or not. RCTs have saved hundreds of millions of lives around the world, and will do so in this . Engaging in this argument is pointless. are in progress as we write these words!

    3 replies 5 retweets 9 likes
    Undo
  7. Retweeted
    10 hours ago
    Replying to and

    Respectfully Prof Mande, do you think we have such actions and mechanisms for Indian journals like IJMR. The journal just published a case control study from ICMR with senior ICMR leadership as co authors. And no COI statement? Is that acceptable?

    4 replies 13 retweets 22 likes
    Undo
  8. Retweeted
    17 hours ago
    Replying to

    A novel virus pandemic is THE time for an expedited RCT *No existing evidence *Quick recruitment (Pandemic, duh!) *Survival at d28 is all that matters- no fancy tests or followup *Could have been completed quickly with reliable results- as trial just did If only!

    2 retweets 5 likes
    Undo
  9. 17 hours ago

    Retweeting again, because I find that a lot of people have not even considered the idea that the beginning of a pandemic may be an excellent time to launch RCTs stat. If you can hand over unproven drug to thousands of people, why can't you do an RCT?

    Hotter-take For any possible therapeutic for COVID19, or any future pandemic 1 If promising, NIH must start immediate RCTs w/ broad IC 2 Docs should not give drugs off-protocol, esp if it jeopardize trial 3 Docs should definitely not tell anecdotes to media (like TPA to the AP)
    Show this thread
    4 replies 8 retweets 38 likes
    Undo
  10. 18 hours ago

    Even seroprevalence can be tricky, but atleast you are not giving a diagnosis to an individual, telling them they are immune, when they may not be

    2 replies 1 retweet 2 likes
    Show this thread
    Show this thread
    Undo
  11. 18 hours ago

    My understanding is that antibody testing is currently only good for seroprevalence. Too many false positives to give a meaningful result to individuals. Thoughts anyone?

    Why are and not allowing private sector to start antibody testing? Instant results in few minutes. Low cost and can give information on prevalence & maybe immune status.Please approve this GOI. Also most are European manufacturers, so quality much better.
    Show this thread
    8 replies 6 likes
    Show this thread
    Show this thread
    Undo
  12. 18 hours ago

    If was so interested in good science, it wouldn't write gushing, one-sided stories about India's HCQ policy without even bothering to talk to good scientists for an alternative view. Here is the alternative view:

    It is worse than flawed when everybody is politicised and playing with people’s lives. This is no science. I wish good scientists won’t dismiss this as a mere ‘flaw’ even if collective...what we’ve seen is criminal dishonesty
    3 replies 16 retweets 35 likes
    Undo
  13. 18 hours ago

    A voice of sanity in a sea of confusion

    I would suggest to Listen to the wisdom of Prof And understand why some of us keep ranting on evidence and policy making
    2 likes
    Undo
  14. Retweeted
    Jun 5

    16. We have some useful data on Lopinivir ritonivir, HCQ, remdesivir... now there are just dozens of drugs docs are giving that we await data for Toci Azithro/ CAP Abx Full dose anticoag TPA Good thing we aren't making all the same errors there Cheers!

    1 reply 6 retweets 30 likes
    Show this thread
    Show this thread
    Undo
  15. Retweeted
    Jun 5

    15. Please do not say RCTs not possible, if you personally give (or preside over an institution that gives) an experimental treatment to 5000 people *cough* jacc letter *cough*

    1 reply 9 retweets 38 likes
    Show this thread
    Show this thread
    Undo
  16. Retweeted
    Jun 5

    13. Use PCR to document outcomes and not self report (ideally budget will permit this) 14. Power trials for REALISTIC effect sizes, not "oh god, wouldn't it be lovely if" effect sizes

    3 replies 5 retweets 23 likes
    Show this thread
    Show this thread
    Undo
  17. Retweeted
    Jun 5

    10. No one should say the word parachute, unless a drug has a 99.9999% mortality benefit in 10 minutes 11. No one should ever talk about the putative molecular action of an agent in the lay press until RCT is positive 12. If a disease is lethal, consider mortality as the endpt

    1 reply 11 retweets 45 likes
    Show this thread
    Show this thread
    Undo
  18. Retweeted
    Jun 5

    7 Trials should use bias resistant endpoints and blinding 8 Trials should have a control arm, not test 2 durations of an experimental drug 9. Trials should be adequately powered (and will be with minimal off protocol use)

    1 reply 9 retweets 26 likes
    Show this thread
    Show this thread
    Undo
  19. Retweeted
    Jun 5

    4. Docs in France should not report 1000 person uncontrolled experiences and denigrate RCTs 5 Politicians should remain quiet 6 No researcher should waste time with retrospective obs studies

    4 replies 25 retweets 56 likes
    Show this thread
    Show this thread
    Undo
  20. Jun 5

    Everyone read this thread

    Hotter-take For any possible therapeutic for COVID19, or any future pandemic 1 If promising, NIH must start immediate RCTs w/ broad IC 2 Docs should not give drugs off-protocol, esp if it jeopardize trial 3 Docs should definitely not tell anecdotes to media (like TPA to the AP)
    Show this thread
    1 reply 4 retweets 5 likes
    Undo
  21. Retweeted
    Jun 5

    First results from the are in. Hydroxycholoquine does not benefit hospitalised patients with -19. "This is not a treatment for covid," say and

    3 retweets 3 likes
    Undo

@PriyankaPulla hasn't Tweeted yet.

Loading seems to be taking a while.

Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

    You may also like

    ·